Clinical trial
Anlotinib in Advanced Solid Tumors With FGFR Alteration
NCT03929965 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anlotinib in Advanced Solid Tumors With FGFR Alteration
- Lead sponsor
- Shanghai Changzheng Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- July 1, 2019
- Completion date
- July 1, 2023
- Enrollment
- 30 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor